« Back to Glossary Index

Mazindol is a stimulant that works similarly to amphetamines, in that it increases alertness and central nervous system stimulation, but, unlike amphetamines, it has little or no effect on mood or the cardiovascular system. It has dopamine and adrenergic blocking properties, and has been shown to be effective for the treatment of both excessive daytime sleepiness and cataplexy in humans, and in canine narcolepsy. While mazindol is not currently approved in the U.S., it was granted Orphan Drug Designation (ODD) status for the treatment of narcolepsy by the U.S. FDA in 2016, and granted ODD status by the European Commission in 2015. Read more about mazindol on HF’s Treatments page HERE.

Get SomnusNooze, our e-newsletter

Sign up to receive HF updates, news from the world of sleep research, first-person stories, and more.

You will receive and email from (please check your junk/spam folder if needed) to confirm your subscription to our newsletter through MailChimp. You are not subscribed until you confirm. Thank you for your interest in Hypersomnia Foundation!